Mast Cell Activation Syndrome (MCAS)

  1. What is MCAS?
  2. The Symptom Triad
  3. Causes and Triggers
  4. SIGHI Criteria and Diagnosis
  5. Tryptase Testing and Biomarkers
  6. Conventional Treatment
  7. Low-Histamine Diet
  8. Mast-Cell-Stabilizing Supplements
  9. Connection to EDS and POTS
  10. Complications
  11. Key Research Papers
  12. Connections

What is Mast Cell Activation Syndrome (MCAS)?

MCAS is a disorder in which mast cells — immune cells found throughout the body — become excessively or inappropriately activated, releasing chemical mediators (histamine, tryptase, prostaglandins, leukotrienes, cytokines) into tissues and the bloodstream. Unlike mastocytosis, where mast cells proliferate abnormally, in MCAS the cell count is normal but their behavior is dysregulated.

Mast cells are sentinel cells stationed at every interface between the body and the outside world: skin, gut lining, airways, and blood vessels. They evolved to defend against parasites and venoms, triggering rapid inflammatory responses. In MCAS, this alarm system fires without adequate cause or cannot be switched off.

Estimated to affect up to 17% of the general population in some research, MCAS remains dramatically underdiagnosed. The condition affects multiple organ systems simultaneously, which is why it is so often mislabeled as anxiety, irritable bowel syndrome, multiple chemical sensitivity, or hypochondria. The average time from symptom onset to correct diagnosis exceeds a decade for many patients.

Back to Table of Contents

The Symptom Triad

The hallmark of MCAS is multi-system symptoms occurring in at least two organ systems simultaneously. Symptoms often arise unpredictably, wax and wane, and are not explained by a single unifying diagnosis.

Skin and vascular:

Gastrointestinal:

Neurological and cardiovascular:

Other common manifestations include frank anaphylaxis or near-anaphylactic episodes, hypersensitivity to medications and foods (reactions to substances most people tolerate without issue), bone pain, respiratory symptoms (wheezing, nasal congestion, throat tightening), and bladder urgency.

Back to Table of Contents

Causes and Triggers

MCAS is classified into three subtypes based on underlying mechanism:

Primary (clonal) MCAS: Caused by somatic mutations in the KIT gene — most commonly the D816V point mutation — producing a population of mast cells with a constitutively active KIT receptor. These mast cells receive a continuous "activate" signal even without external stimulus. Primary MCAS exists on a spectrum with indolent systemic mastocytosis; the distinction lies in mast cell burden and bone marrow findings.

Secondary MCAS: Mast cell activation driven by an upstream condition — chronic infection (Lyme disease, EBV, Bartonella), autoimmune disease, IgE-mediated allergy, or mechanical triggers such as connective tissue laxity. Treating the underlying condition can reduce MCAS severity in secondary cases.

Idiopathic MCAS: The most common category — no identifiable primary mutation or secondary driver. Likely involves polygenic susceptibility combined with environmental and epigenetic factors.

Common triggers that provoke mediator release:

Over time, the trigger threshold can lower — a phenomenon called sensitization. Stimuli that were previously well-tolerated begin provoking reactions, leading to a progressively narrowing diet and environmental exposure list. Early aggressive treatment can interrupt this cycle.

Back to Table of Contents

SIGHI Criteria and Diagnosis

MCAS diagnosis is clinical — there is no single confirmatory blood test. The most widely used framework is the consensus criteria published by Valent et al. (2020), which requires all three of the following:

  1. Symptoms: Clinical features consistent with mast cell mediator release occurring in two or more organ systems, recurring over time
  2. Biomarker elevation: A documented rise in mast cell–specific mediators above individual baseline during symptoms (not just above population reference ranges)
  3. Treatment response: Meaningful symptom reduction with mast-cell-targeted therapy (antihistamines, mast cell stabilizers, or mediator blockers)

The SIGHI (Swiss Interest Group Histamine Intolerance) scoring system provides a practical questionnaire-based screening tool, rating symptoms across organ systems on a 0–3 severity scale. A total score above a threshold suggests clinically significant mast cell or histamine dysregulation.

Rule-out diagnoses that must be excluded before confirming MCAS:

Because workup requires multiple timed collections during symptomatic episodes, patients are often instructed to keep a reaction kit at home — containing chilled urine collection containers and a note to draw serum tryptase within 4 hours of onset.

Back to Table of Contents

Tryptase Testing and Biomarkers

Serum tryptase is the most specific readily available mast cell biomarker. Tryptase is stored almost exclusively in mast cell granules, making it highly specific (unlike histamine, which is also produced by basophils and platelets). However, the majority of MCAS patients have normal baseline tryptase — other mediators are more informative in most cases.

Diagnostic criteria for tryptase:

Other informative mediator tests:

Hereditary alpha-tryptasemia (HAT): Caused by extra copies of the TPSAB1 gene encoding alpha-tryptase. Affected individuals have elevated baseline tryptase, heightened allergic responses, multisystem complaints overlapping with MCAS, and a familial inheritance pattern. HAT and MCAS frequently co-occur, with TPSAB1 duplications acting as a severity amplifier. Testing is available through specialized labs via gene copy number analysis.

Practical note: Urine collections must be acidified (acetic acid preservative) and kept refrigerated to prevent histamine degradation. Samples collected without proper acidification produce falsely low results. Many commercial labs do not acidify by default — confirm before ordering.

Back to Table of Contents

Conventional Treatment

Treatment is layered — avoid triggers, stabilize mast cells, block the mediators they release, and address residual symptoms. Because tolerance to medications varies unpredictably in MCAS, new drugs should be introduced one at a time, at low doses.

First-line antihistamines (block histamine already released):

Mast cell stabilizers (prevent degranulation):

Prostaglandin blockade: Low-dose aspirin (81–325 mg daily) inhibits prostaglandin D2 synthesis via COX-1/COX-2 and benefits a significant subset of MCAS patients. However, aspirin is also a potent trigger in others (COX inhibition shifts arachidonic acid toward leukotriene production). An aspirin challenge should be performed under medical supervision.

Biologics:

Epinephrine auto-injector: All MCAS patients with a history of anaphylaxis or near-anaphylactic reactions must carry two epinephrine auto-injectors (EpiPens) at all times. Epinephrine remains the only treatment that reverses anaphylaxis.

Corticosteroids: Short-course prednisone for acute severe flares only. Long-term use is generally avoided due to immune suppression, bone loss (compounding the osteoporosis risk already elevated in MCAS), and adrenal suppression.

Back to Table of Contents

Low-Histamine Diet

Histamine is both a mast cell mediator and a dietary substance. When mast cells are already releasing excess histamine into tissues, the additional histamine load from food can push the body over the symptom threshold. Reducing dietary histamine gives the body's histamine-degrading enzymes — diamine oxidase (DAO) in the intestinal wall and histamine N-methyltransferase (HNMT) in the liver and brain — a better chance of keeping pace.

Foods highest in histamine (formed during fermentation, aging, and bacterial action):

Histamine liberators (trigger mast cells to release endogenous histamine, independent of their own histamine content):

DAO-blocking substances (inhibit the enzyme that degrades ingested histamine):

The low-histamine diet is an elimination protocol, not a permanent prescription. Most patients find their dietary tolerance expands significantly once mast cell stabilizers take effect. The goal is to reduce total histamine burden while other treatments are established — not to restrict indefinitely. A dietitian experienced with histamine intolerance can help reintroduce foods systematically.

Back to Table of Contents

Mast-Cell-Stabilizing Supplements

Several nutritional compounds have evidence for direct mast cell stabilization or histamine degradation support. These are adjuncts to — not replacements for — prescription treatment. Introduce one at a time given the unpredictable reactivity of MCAS patients.

Quercetin: A flavonoid polyphenol with the most robust direct evidence for mast cell stabilization. Quercetin inhibits IgE-mediated histamine release, suppresses degranulation by blocking calcium influx, and reduces cytokine production (TNF-α, IL-6). Typical dose: 500–1000 mg twice daily with meals. Quercetin bioavailability is enhanced by combining with bromelain or choosing phytosomal formulations (Quercefit). The Quercetin page has full detail on mechanisms and dosing.

Vitamin C (ascorbate): Co-factor for the DAO enzyme — without adequate vitamin C, DAO cannot efficiently degrade ingested histamine. Additionally, vitamin C degrades histamine directly and has broad anti-inflammatory effects. Typical dose: 1–3 g daily in divided doses (buffered or liposomal forms tolerated better by sensitive patients). Doses above 2 g/day may cause loose stools — start low.

DAO enzyme supplements: Oral diamine oxidase products (e.g., DAOSiN, Histamine Block, Seeking Health HistaminX) contain porcine-derived DAO enzyme. Taken 15–30 minutes before high-histamine meals, they degrade histamine in the gut before it can be absorbed. Useful as a situational tool when dietary compliance is difficult (travel, social eating).

Luteolin: A flavonoid closely related to quercetin, found in celery, parsley, thyme, and chamomile. Inhibits mast cell degranulation and blocks STAT3 signaling downstream of mast cell activation. Available as a supplement (e.g., Neuroprotek); effective doses in research are 100–200 mg daily.

Omega-3 fatty acids (EPA/DHA): Reduce synthesis of prostaglandin D2 and leukotriene B4 by competing with arachidonic acid in the COX and LOX pathways. Also reduce expression of mast cell surface receptors. Typical therapeutic dose: 2–4 g EPA+DHA daily from purified fish oil. Choose distilled or molecular-filtered products to avoid histamine from oxidized fish oil.

Magnesium: Inhibits substance P release from nerve fibers adjacent to mast cells, reducing neurogenic mast cell activation. Also a cofactor in dozens of anti-inflammatory pathways. Magnesium glycinate or malate preferred in sensitive patients (oxide and chloride forms more likely to cause GI reactions). Dose: 200–400 mg daily.

Resveratrol: Stilbene polyphenol from grapes and Japanese knotweed. Inhibits mast cell activation via the Syk kinase signaling pathway and suppresses NF-κB-driven mediator production. Typical dose: 200–500 mg daily. Note: resveratrol is found in red wine, but the histamine content of red wine far outweighs any resveratrol benefit in MCAS.

B6 (pyridoxal-5-phosphate): Active form of B6 is a cofactor for DAO. Some MCAS patients with impaired B6 metabolism show improved histamine tolerance with P5P supplementation. Limit to physiological supplementation doses (25–50 mg P5P daily) — high-dose B6 is neurotoxic (see Vitamin B6).

Back to Table of Contents

Connection to EDS and POTS

MCAS, hypermobile Ehlers-Danlos Syndrome (hEDS), and Postural Orthostatic Tachycardia Syndrome (POTS) form a recognized and well-documented triad. In clinical practice, diagnosing one of these three conditions substantially raises the likelihood of the other two.

Why they co-occur — proposed mechanisms:

Extended overlap: The triad also overlaps with fibromyalgia, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), and long COVID. Many patients receive diagnoses of all three conditions over time, often from different specialists who are unaware of the others' diagnoses. A coordinating physician who understands the full picture is crucial.

Treatment implications: In patients with all three conditions, treatment sequencing matters. Treating MCAS first often reduces POTS symptom severity by decreasing vasodilation and mast-cell-driven dysautonomia. Compression garments and salt/fluid loading for POTS can paradoxically improve MCAS by reducing hemodynamic triggers.

Back to Table of Contents

Complications

Anaphylaxis: The most immediately life-threatening complication. MCAS patients may experience anaphylaxis with no identifiable trigger (idiopathic anaphylaxis). Epinephrine auto-injectors must be carried at all times; patients should never be alone during severe reactions.

Osteoporosis and fracture: Mast cell mediators — particularly histamine, prostaglandins, TNF-α, and heparin — directly stimulate osteoclast activity and inhibit osteoblast differentiation. MCAS patients have significantly elevated rates of bone density loss, sometimes preceding diagnosis by years. Baseline DEXA scanning and calcium/vitamin D supplementation are standard preventive measures.

Severe malnutrition: The combination of a restrictive low-histamine diet, GI dysmotility, and food-triggered reactions can lead to progressive dietary restriction and significant nutritional deficiency. In severe cases, elemental formulas or parenteral nutrition may be required.

Medication intolerance: Many MCAS patients react to excipients (dyes, preservatives, binders) in pharmaceutical tablets and capsules rather than to the active drug itself. Compounding pharmacies that can produce dye-free, preservative-free formulations are invaluable for this population.

Progression to systemic mastocytosis: In a minority of patients with primary (clonal) MCAS, mast cell burden increases over time and the condition progresses to indolent or smoldering systemic mastocytosis. Annual monitoring with serum tryptase is appropriate for patients with documented KIT mutations.

Psychiatric comorbidity: Anxiety and depression are nearly universal in MCAS — partly because histamine is a neuroexcitatory neurotransmitter that directly generates anxiety-like states, and partly because living with unpredictable, invalidated symptoms for years takes a psychological toll. The anxiety is not imaginary or primary; it is histamine-driven and often resolves significantly with effective MCAS treatment.

Back to Table of Contents

Key Research Papers

  1. Valent P et al., 2019 — PMID: 31476418 — Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome. J Allergy Clin Immunol Pract.
  2. Afrin LB et al., 2017 — PMID: 28552211 — Characterization of mast cell activation syndrome. Am J Med Sci.
  3. Theoharides TC et al., 2012 — PMID: 21185371 — Mast cells and inflammation. Biochim Biophys Acta.
  4. Hamilton MJ et al., 2011 — PMID: 21281936 — Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations. J Allergy Clin Immunol.
  5. Castells M et al., 2014 — PMID: 25459580 — Mast cell activation syndrome. Immunol Allergy Clin North Am.
  6. Molderings GJ et al., 2011 — PMID: 21418662 — Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. J Hematol Oncol.
  7. Molderings GJ et al., 2013 — PMID: 23704980 — Familial occurrence of systemic mast cell activation disease. PLoS ONE.
  8. Schwartz LB et al., 2004 — PMID: 15474676 — Serum tryptase levels and the diagnosis of anaphylaxis. Clin Lab Med.
  9. Lieberman PL et al., 2006 — PMID: 16802760 — Epidemiology of anaphylaxis: findings of the American College of Allergy, Asthma and Immunology Epidemiology of Anaphylaxis Working Group. Ann Allergy Asthma Immunol.
  10. Akin C et al., 2017 — PMID: 27919917 — Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood.
  11. Lyons JJ et al., 2016 — PMID: 27749843 — Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet.

PubMed Topic Searches

Back to Table of Contents

Connections